| Dr David Earl Thompson, MD | |
|
5115 Bernard Dr, Suite 201, Roanoke, VA 24018-4357 | |
| (540) 345-0289 | |
| (540) 345-9569 |
| Full Name | Dr David Earl Thompson |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 43 Years |
| Location | 5115 Bernard Dr, Roanoke, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265410559 | NPI | - | NPPES |
| 1265410559 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 0101046099 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carilion Medical Center | Roanoke, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Acv Inc | 3870633936 | 60 |
News Archive
A new study suggested that an estimated 7% of American teens and adults carry the human papillomavirus in their mouths. This may help health experts finally understand why rates of mouth and throat cancer have been climbing for nearly 25 years. The evidence additionally makes it clear that oral sex practices play a key role in transmission.
A new study from the Regenerative Bioscience Center at the University of Georgia is the first to suggest that COVID-19 does not directly damage taste bud cells.
A report by the US Centers for Disease Control and Prevention (CDC) has shown there is still disparity between African-Americans (blacks) and whites in terms of life expectancy.
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
The Medical Research Council (MRC) is to fund a research proposal from a team at the North East England Stem Cell Institute (NESCI) for a project to find ways of improving the efficiency of therapeutic cloning - a technique which would allow scientists to create patient-specific stem cells and develop regenerative therapies for many debilitating conditions such as diabetes, heart disease and Parkinson's disease.
› Verified 6 days ago
| Entity Name | Acv Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881927259 PECOS PAC ID: 3870633936 Enrollment ID: O20091221000602 |
News Archive
A new study suggested that an estimated 7% of American teens and adults carry the human papillomavirus in their mouths. This may help health experts finally understand why rates of mouth and throat cancer have been climbing for nearly 25 years. The evidence additionally makes it clear that oral sex practices play a key role in transmission.
A new study from the Regenerative Bioscience Center at the University of Georgia is the first to suggest that COVID-19 does not directly damage taste bud cells.
A report by the US Centers for Disease Control and Prevention (CDC) has shown there is still disparity between African-Americans (blacks) and whites in terms of life expectancy.
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
The Medical Research Council (MRC) is to fund a research proposal from a team at the North East England Stem Cell Institute (NESCI) for a project to find ways of improving the efficiency of therapeutic cloning - a technique which would allow scientists to create patient-specific stem cells and develop regenerative therapies for many debilitating conditions such as diabetes, heart disease and Parkinson's disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Earl Thompson, MD 5115 Bernard Dr, Suite 201, Roanoke, VA 24018-4357 Ph: (540) 345-0289 | Dr David Earl Thompson, MD 5115 Bernard Dr, Suite 201, Roanoke, VA 24018-4357 Ph: (540) 345-0289 |
News Archive
A new study suggested that an estimated 7% of American teens and adults carry the human papillomavirus in their mouths. This may help health experts finally understand why rates of mouth and throat cancer have been climbing for nearly 25 years. The evidence additionally makes it clear that oral sex practices play a key role in transmission.
A new study from the Regenerative Bioscience Center at the University of Georgia is the first to suggest that COVID-19 does not directly damage taste bud cells.
A report by the US Centers for Disease Control and Prevention (CDC) has shown there is still disparity between African-Americans (blacks) and whites in terms of life expectancy.
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
The Medical Research Council (MRC) is to fund a research proposal from a team at the North East England Stem Cell Institute (NESCI) for a project to find ways of improving the efficiency of therapeutic cloning - a technique which would allow scientists to create patient-specific stem cells and develop regenerative therapies for many debilitating conditions such as diabetes, heart disease and Parkinson's disease.
› Verified 6 days ago
Dr. David S. Hunt, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 5115 Bernard Dr, Suite 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 | |
Dr. Teodulo Remandaban, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 5115 Bernard Dr, Suite 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 | |
Dr. Elizabeth H. Duckworth, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 5115 Bernard Dr, Suite 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 | |
Dr. Charles K. Gadpaille, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 5115 Bernard Dr, Suite 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 | |
Dr. George Landon Smith, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5115 Bernard Dr Ste 201, Roanoke, VA 24018 Phone: 540-345-0289 | |
Dr. Neil A. Macdonald, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5115 Bernard Dr Ste 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 | |
Dr. Patrick Banner Robertson, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5115 Bernard Dr Ste 201, Roanoke, VA 24018 Phone: 540-345-0289 Fax: 540-345-9569 |